Table 2.

Basic characteristic table

Author\Year \Country	study design	Study period	ET cycle	Intervention group	Control group	Definition of RIF	Outcomes
Kalem 2020 Turkey	RCT	2016.3–2017.12	Fresh cycle	Administered 30 mIU/ml of Leucotomy®(Filgrastim [G-CSF]; DEM Medical, Dong-A; South Korea) through slow infusion into the endometrial cavity using a soft embryo transfer catheter	1 mL normal saline of infused into the endometrial cavity in the same way as the intervention group	Failure to achieve a clinical pregnancy after the transfer of at least four good-quality embryos in a minimum of three fresh or frozen cycles to a woman under the age of 40 years	Endometrial thickness; clinical pregnancy rate. Live birth rate
Huang 2020 China	RCT	2015.12–2017.7	Frozen cycle	Administered a 1-ml uterine infusion of recombinant human G-CSF (150 mg, 1 ml, Rubbia, Shandong) through an intrauterine insemination (IUI) catheter	1. n = 52 intrauterine infusion of saline solution in the same way as the intervention group; 2. n = 59 no treatment	At least two previous implantation failures	Clinical pregnancy rate miscarriage rate; live birth rate
Scarpellini 2019 Italy	RCT	Not reported	Frozen cycle	Subcutaneous GM-CSF 1.5 mg/kg/daily (60–100) from the day of embryo transfer to the day of b-hcg HCG	Subcutaneous saline solution infusion in the same way as the intervention group	At least 9 good embryos previously transferred, women less than 38 years old	Pregnancy rate
Arefi 2018 Iran	RCT	2010.5–2015.10	Fresh cycle	Recombinant human G-CSF 300 μg (0.5 ml) subcutaneously injected 30 min before blastocyst embryo transfer	Not reported	More than three previous IVF-ET failures	Live birth rate; clinical pregnancy rate
Tanha 2016 Iran	RCT	2011.12–2014.1	Frozen cycle (n = 9) Fresh cycle(n = 91)	G-CSF 300 m0mg/1 m1ml was administered at the day of oocyte puncture or day of progesterone administration of FET cycle	40 in the saline group;20 in the placebo group	At least three implantation failures with history of transferring at least four good-quality embryos without uterine or thrombophilia factors	Pregnancy rate; implantation rate
Aleyasin 2016 Iran	RCT	Not reported	Frozen cycle	Subcutaneous 300 μg GCSF before implantation	Not reported	Not reported	Implantation rate; chemical pregnancy rate; clinical pregnancy rate
Obidniak 2016 Iran	RCT	Not reported	Frozen cycle	1. Study group No 1: intrauterine perfusion with G-CSF (filgrastim 30 million IU, 1 mL) using insemination catheter 5 days prior to embryo transfer ;2. Study group No 2: G-CSF (filgrastim 30 million IU, 1 ml) was administered subcutaneously once at on the day of embryo transfer	No therapy	At least two cycles of in vitro fertilization in which good-quality embryos (Gardner blastocyst grading system) were transferred in each cycle without achieving a clinical pregnancy	Implantation rate; clinical pregnancy rate
Maryam 2016 Iran	RCT	2014.10–2015.2	fresh cycle	G-CSF 0.5 ml (300 μg/ml) GCSF was infused intrauterine infusion in intervention group	Not reported	Women between 20 and 40 years old with history of at least two implantation failures	Implantation rate; clinical pregnancy rate
Abedi 2015 Iran	RCT	Not reported	Not reported	Subcutaneous 300 m0mg GCSF before implantation	Not reported	Infertile women with normal endometrial thickness who had 2 implantation failures after IVF cycles	Implantation rate chemical pregnancy rate; clinical pregnancy rate